ReviewJournal of personalized medicine2024
Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium.
Review in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prostate cancer in Nigeria: a scoping review and meta-analysis of current evidence on process indicators and interventions.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2025Pooled it
- Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial.International journal of cancer · 2026Trial
- Implementation and First Results of the Czech Nationwide Prostate Cancer Screening Pilot Program.European urology open science · 2026Article
- Mapping the readiness landscape for prostate cancer screening in Europe: analysis of health system capacity across the PRAISE-U pilots.EClinicalMedicine · 2026Article
- Digital twin technologies in prostate cancer as a frontier for precision medicine.European radiology experimental · 2026Review
- International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study.The Lancet. Oncology · 2026Article
- The 5-year outcomes of a regional population-based PSA information and testing programme.BJU international · 2026Article
- Prostate Cancer Incidence, Mortality, and Survival in Switzerland.JAMA network open · 2026Article
- Prostate cancer screening in Europe: future directions and perspectives.Prostate cancer and prostatic diseases · 2026Review
- A guide to cancer screening.Nature reviews. Clinical oncology · 2026Review
- Evaluating the impact of age on prostate cancer overdiagnosis using long-term follow-up from a randomised trial.medRxiv : the preprint server for health sciences · 2026Article
- Article
- Prediagnosis Prostate-Specific Antigen Testing History in Patients With Incident Prostate Cancer.JAMA network open · 2025Article
- Role of prostate health index (PHI) in prostate cancer screening: cost minimization analysis through simulation modelling.World journal of urology · 2025Observational
- Multiple highly methylated CpG sites as potential epigenetic markers for the diagnosis of prostate cancer.Clinical epigenetics · 2025Article
- Prostate cancer incidence and mortality among immigrants in Finland between 2000 and 2017 - a register-based cohort study.Acta oncologica (Stockholm, Sweden) · 2025Article
- Article
- Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update.European urology · 2025Article
- Article
- Meeting Highlights The 4th Marie Skłodowska-Curie Symposium on cancer research and care: Mechanisms of support for regional & international collaborations.Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
With the new policy recommendation in 2022 to explore the possibilities of screening for prostate cancer by the European Commission, the landscape for prostate cancer early detection is evolving. In line with this recommendation, the PRAISE-U project aims to evaluate the early detection and diagnosis of prostate cancer through customised and risk-based screening programmes, with the goal to align protocols across European Union member states. This systematic review is part of the PRAISE-U project, with the goal to review the policy, medical guideline recommendations, and the current level of opportunistic screening presented in the scientific literature on prostate cancer early detection from 2016 to 2023 in European Union member states. An extensive literature search was performed on 1 June 2023 in a large number of databases, including Embase.com, Medline (Ovid), Web of Science Core Collection, Google Scholar, and Policy Commons. We identified 318 articles (qualitative, quantitative, and reviews), of which 41 were included in the full-text screening. Seventeen articles were ultimately identified as eligible for inclusion. The included articles revealed significant variations towards PSA-based early detection policies for prostate cancer in nine European countries. Despite official recommendations, opportunistic screening was prevalent across all nine countries regardless of recommendations for or against PSA-based early detection. This systematic review suggests that the current early detection policies are not fit for purpose. High levels of opportunistic screening and overdiagnosis persist, prompting policy recommendations for standardised guidelines, informed decision making, and increased awareness to improve efficiency and effectiveness in early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.